Alzamend Neuro Lines Up $25M from Affiliate as Nasdaq Flags Board Independence

summarizeSummary

Alzamend Neuro entered a $25M convertible preferred stock deal with affiliate Ault Lending, closing $7.5M upfront. The floating conversion price and deep discount potential pose severe dilution risk. The company also faces Nasdaq non-compliance for board independence.

check_boxKey Events · Financing and Capital Events · ALZN

• $25M Financing with Affiliate

  A Securities Purchase Agreement with Ault Lending, LLC provides for up to $25 million in Series D convertible preferred stock. The initial $7.5 million tranche closed on July 31, 2026, with a second $2.5 million tranche due after a registration statement is effective, and up to $15 million in monthly $1 million installments thereafter.

• Highly Dilutive Conversion Terms

  Each $1,050 stated value preferred share converts at the greater of $0.2668 (floor) or 80% of the lowest closing bid price over the five trading days prior to conversion, capped at $2.00. At the current $1.35 stock price, the conversion price could be as low as $1.08, implying significant potential dilution. The initial $7.5 million tranche alone could convert into up to 6.94 million shares, nearly doubling the outstanding share count.

• Nasdaq Board Independence Deficiency

  Following the death of independent director Lynne Fahey McGrath on July 20, 2026, the company fell below Nasdaq's majority independent board requirement. Nasdaq granted a cure period until the earlier of the next annual meeting or July 20, 2027, but if the annual meeting is before January 18, 2027, compliance must be achieved by that date.

• Investor Rights and Future Dilution Overhang

  Ault Lending received a right of first refusal on future financings for three years after it no longer holds preferred shares, a participation right for 33.33% of subsequent offerings, and most favored nation protection. The company must also seek shareholder approval to issue shares beyond 19.99% of outstanding common stock, with a proxy statement due within 15 days.

auto_awesomeAnalysis · ALZN · Life Sciences

With only $711K in cash and a going concern warning, micro-cap biotech Alzamend Neuro has secured a $25 million Series D convertible preferred stock financing from affiliate Ault Lending. The initial $7.5 million tranche closed immediately, delivering critical near-term liquidity. The terms, however, are highly dilutive: the conversion price is set at 80% of the lowest closing bid price over five days, with a floor of $0.2668, allowing the investor to convert at a deep discount to the current $1.35 stock price. The deal also includes a right of first refusal on future financings, board observer rights, and a requirement to seek shareholder approval for issuance beyond 19.99% of outstanding shares. Separately, the company disclosed a Nasdaq notice for failing to maintain a majority independent board after a director's passing, with a cure period until July 2027. This adds to existing delisting risk from the stock's low price. The financing buys time but at a steep cost to existing shareholders.